Objective There are many adverse reactions due to clindamycin, but kidney diseases (acute kidney injury, AKI) are uncommon. However, in recent years, the rate of clindamycin-induced kidney diseases has increased. We analyzed 50 patients with clindamycin-induced kidney diseases retrospectively, and investigated the characteristics of these kidney diseases in order to provide a reference for rational clinical drug use and to reduce drug-induced organ damage. Methods We investigated 50 patients diagnosed with clindamycin-induced kidney diseases retrospectively at the Department of Nephrology, Shandong University Qilu Hospital, from January 2009 to December 2013. The parameters included in our study were age, sex, clinical manifestations, efficacy and prognosis. Results All patients were diagnosed with clindamycin-induced kidney diseases within 48 hours of the application of clindamycin at 1.0-2.0 g/day. The patients included 29 women and 21 men. Most of the enrolled patients were 20-59 years old. Fifty-one patients were diagnosed with AKI stage 3 upon admission. Thirtythree had episodes of gross hematuria, but fever, skin rash and eosinophilia were rare. Urine analysis revealed mild proteinuria and severe tubular dysfunction. In the majority of patients, AKI was severe and required renal replacement therapy, but renal function in all patients had recovered significantly two months after discharge. Conclusion Clindamycin-induced AKI is largely reversible and is associated with episodes of gross hematuria. Clinicians should use clindamycin rationally and reduce the incidence of adverse reactions.
Introduction
Clindamycin, derived from lincomycin, is a broadspectrum macrolide antibiotic that is primarily used for infections of anaerobic bacteria and sensitive gram-positive bacteria. It shows excellent antibacterial activity and good oral absorption, and is widely distributed in the body (except in cerebrospinal fluid), with particularly high concentrations in bone tissue and bile. Because it does not require a skin test, clindamycin has been used widely in a clinical context. However, with its widened range of applications, adverse reactions also increased, involving multiple organs including kidney.
Acute kidney injury (AKI) is a broad clinical syndrome defined by an abrupt decrease in kidney function within 48 hours, caused by various etiologies. Its incidence has increased dramatically in recent years. According to many studies, various kinds of drug can cause AKI, accounting for nearly 20% of total cases at all levels of medical units. All kinds of nonsteroidal anti-inflammatory drugs and antibiotics account for a large proportion of the drugs that can cause kidney diseases. Clindamycin is a commonly used antibiotic with broad antimicrobial activity, and many adverse reactions of clindamycin have recently been identified. In the present paper, we report on 50 patients with clindamycin-induced AKI and describe its characteristics. 
Materials and Methods
In the present study, a total of 50 patients with clindamycin-induced AKI were enrolled and examined at the Department of Nephrology, Shandong University Qilu Hospital, Shandong Province, China, between January 2009 and December 2013. The patients enrolled in this study had been diagnosed with AKI caused by clindamycin; in the same period, there were over 230 patients with clindamycin-induced AKI, but only 57 patients agreed to undergo a renal biopsy, and we collected 50 patients as research subjects. All 50 patients included in this report met the following criteria: (1) no previous history of underlying chronic kidney disease, (2) fulfilling the Acute Kidney Injury Network (AKIN) criteria of AKI within 72 hours after the infusion of clindamycin and (3) no obvious alternative causes of AKI (e.g., volume insufficiency, septic shock, urinary obstruction or hemorrhagic fever with renal syndrome). All enrolled subjects had no history of kidney diseases, diabetes mellitus, liver dysfunction or dyslipoproteinemia before the diagnosis of clindamycin-induced AKI.
Peripheral blood was obtained from all enrolled patients in the morning after fasting for eight hours in order to determine the levels of blood urea nitrogen (BUN) and serum creatinine (Scr). The age, sex, clinical manifestations and total time from onset to a normal state were recorded. In all enrolled patients, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were determined. Glomerular filtration rate (GFR) was calculated using the Modification of Diet in 
Statistical Analysis
The Excel and SPSS17.0 software programs were used for the statistical analysis and the t-test was used for a correlation analysis. All p values were two-sided, and <0.05 was used as the criterion of significance.
Results

Characteristics of the cases
The clinical and biological characteristics of the patients at the time of AKI diagnosis are summarized in Table 1 . The cohort of 50 patients had a male:female ratio of 21:29. The mean age was 41.1±14.7 years (range: 19-79). The BUN and Scr were normal in the selected patients before the application of clindamycin (according to the patients' own accounts), but the levels of BUN and Scr in every patient on admission were higher than normal (average, BUN 23.2±8.09 mmol/L, Scr 696.1±174.7 μmol/L, GFR 10.31 mL/min·1.73 m 2 ). Both SBP and DBP were elevated (average, SBP 151.1±23.0 mmHg and DBP 90.3.1±17.1 mmHg). Proteinuria was found in 31 patients (62%), the level of proteinuria in routine urinary checks was almost ± -++ (qualitative) (average 0.75±0.19 g, quantitative) and β2 microglobulin in urine was increased in almost all patients (48 cases, 96%; average 13.7±2.1 mg/L, normal range 0-0.22 mg/L). Gross hematuria was seen in 21 patients (42%). Upper respiratory infection (39/50, 78%) and gastroenteritis (7/ 50, 14%) were the most common reasons for clindamycin therapy. Other diseases included cholecystitis (2/50, 4%), gingivitis (1/50, 2%) and beriberi (1/50, 2%) ( Table 2) .
Clinical manifestations
The common doses of clindamycin in the selected cases were 0.75-1.25 g, by intravenous infusion twice daily. The average onset of AKI occurred 1.5 days after the first dosage (range: 0.7 hours to 3.5 days). None of the enrolled patients had a history of disease before the application of clindamycin and they were in a healthy state. On admission, anuria, oliguria, hematuria, proteinuria and edema were seen in the patients (Table 3 ). There was evidence of metabolic acidosis (serum bicarbonate lower than normal), electrolyte abnormalities (77% of enrolled patients had high serum potassium), impairment of concentrating capacity (low urine specific gravity), allergic/inflammatory mechanism (urine 
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Masson staining (×400) Periodic acid silver methenamine staining (×400) Hematoxylin and Eosin staining (×400) eosinophils elevated in almost 93% of cases, blood eosinophils increased in 86%) and decreased urinary pH. In addition to kidney damage, clinical manifestations in other systems included the following: (i) gastrointestinal system: nausea, vomiting, abdominal pain and diarrhea; (ii) musculoskeletal system: myalgia and back pain; (iii) skin and appendages: rash, itching and sweating; (iv) fever; (v) dyspnea; (vi) liver dysfunction; and (vii) circulatory system: palpitations and tachycardia (Table 3 ). The average time of peak serum creatinine values was 10.4 days after the application of drugs.
Pathology of renal biopsy
Renal biopsy was performed at the polyuric stage in every enrolled case with AKI because the reason for the injury was unclear in the patients. No immune complex was found to be deposited in the glomerulus by immunofluorescence. On light microscopy, acute tubular necrosis (ATN) was found in all specimens, while renal tubulitis was identified in 41 (82%) of the patients. There were renal epithelial cells, neutrophils, dysmorphic red blood cells and occasionally eosinophils detected in the renal tubular lumen (Figure) . Renal tubular epithelial cells became flat or swollen, the tubular lumen expanded and the brush border of tubular cells disappeared. Red cell cast was seen in the tubular lumen. No granuloma was detected. There was focal fibrosis in the renal interstitial region with a small amount of lymphocyte infiltration. Thirty-six patients (72%) were diagnosed with acute interstitial nephritis (AIN) and 10 (20%) were diagnosed with ATN. The artery walls in the interstitial region were thickened and vascular endothelial cells were swollen ( Figure, provided as a representative of a biopsy) .
Outcome of patients
At an average of seven days after admission, the levels of BUN and Scr were the highest. Average BUN was 39.7± 11.3 mmol/L and Scr was 903.7±170.3 μmol/L, while the GFR was only 6.43 mL/min·1.73 m 2 , so all enrolled patients accepted renal replacement therapy, with other symptomatic and supportive treatments. Forty-three patients (86%) received oral prednisone (average 30 mg/day). Continuous renal replacement therapy was performed in 40 patients (80%) and 10 patients (20%) were dialyzed intermittently. After an average of approximately 14 days of treatment, most patients recovered to a healthy state (33/50, 66%), with normal levels of BUN and Scr. Clinical symptoms and laboratory examination results were improved in 17 cases with increased urine output and decreased serum creatinine, but they did not return to normal levels. Mortality was zero in the present study (Table 4) .
Discussion
Clindamycin is a lincosamide antibiotic, developed in 1966 by chemically modifying the naturally occurring lincomycin. It is a potent inhibitor of bacterial protein biosynthesis, and it has usually been recommended as an antibiotic for both beta-hemolytic streptococcus and Streptococcus pneumoniae infections in human and veterinary medicine. For several decades, there has been an increase in interest in the use of clindamycin since it reaches high intracellular levels in phagocytic cells, high levels in bone and appears to have an antitoxin effect. In spite of the expanded use of clindamycin, the adverse reactions (ADRs) of this antibiotic are minor. Its gastrointestinal side effects have been reported, including diarrhea, nausea, vomiting, flatulence, metallic taste, anorexia and esophagitis. Drug fever, eosinophilia, erythema multiforme and urticaria have also been reported. In addition, injection-site pain, swelling and thrombophlebitis have been reported with the use of intravenous and intramuscular clindamycin. However, clindamycininduced kidney diseases have rarely been reported. The incidence of ADRs associated with clindamycin has been increasing recently. Huang et al. and Li et al. reported 248 adverse reactions associated with clindamycin, including two cases (0.8%) of hematuria (2, 3) . Xia also reported that there were 16 cases of clindamycin-induced kidney injury in 1996-2006, according to China Digital Journal.
Fifty cases of clindamycin-induced AKI from January 2009 to December 2013 encountered at our departments were collected in the present study, in which the influence of other renally toxic drugs and a history of chronic kidney disease were ruled out. In these patients, there was a higher incidence of clindamycin-induced AKI in women than in men (29:21), and the vast majority of patients were middleaged (average age, 41.1±14.7 years). On admission, the concentrations of BUN and Scr in serum were increased in all patients, while the level of hemoglobin (Hgb) was decreased to below the normal range. The elevation of sensitive urinary markers demonstrated tubulo-interstitial defect. In the present study, the main reason for applying clindamycin was that there were inflammatory diseases in the enrolled patients, including upper respiratory infection (78%) and gastroenteritis (14%). In terms of the clinical manifestations of clindamycin-induced AKI, 62% of enrolled patients presented proteinuria and 42% of cases showed hematuria. Nausea, vomiting, abdominal pain and diarrhea were seen in 62% of cases. Oliguria and edema were also common. Palpitations, tachycardia and dyspnea were relatively rare.
Clindamycin is extensively metabolized in the liver, most likely by the cytochrome P450 isoenzyme 3A4, but only 10% of the drug is excreted by the kidneys. Because of its high concentration in urine, clindamycin may lead to tubular obstruction and injury, and urinary laboratory tests showed abnormal results. Hematuria, especially gross hematuria, is believed to be secondary to drug crystallization because of tubular damage and the crystallization can conversely cause kidney damage (4, 5) .
Retrospective studies have been undertaken to assess the prevalence and the clinical and biochemical features of AKI following clindamycin treatment (6) (7) (8) . AKI related to the administration of clindamycin is generally associated with oligoanuria, the same as in our patient. Various mechanisms of clindamycin-associated AKI have been postulated, but it is difficult to determine the incidence of AKI among all patients treated with clindamycin. The mechanism of clindamycin-induced AKI is variable and may include ATN, AIN, hemodynamic perturbations and tubular obstruction due to drug crystallization (9, 10). Conversely, not all patients treated with clindamycin develop kidney diseases. The exact mechanism of clindamycin-induced AKI requires further study (11) (12) (13) .
Conclusion
In summary, we herein described 50 patients with clindamycin nephrotoxicity. The clinical manifestations were characterized by transient AKI with an impaired renal tubular function. Drug hypersensitivity is the most common and important etiological factor for this condition. The pathogenesis of AKI has not yet been defined. Renal biopsy is perhaps the "gold standard" for the diagnosis, but in the present study, many patients refused to undergo renal biopsy. Despite the presence of severe renal failure, the outcomes were quite good, so clindamycin-induced kidney diseases should not be overlooked at all levels of medical institutions.
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